Rexahn Pharmaceuticals Inc. is standing at a crossroads. The Rockville biotech announced Tuesday an intention to consider “strategic alternatives” as it cuts staff and searches for ways to extend resources. Potential moves include a merger or acquisition, reverse merger or other business combination. It could also mean licensing or selling off its assets. CEO Doug Swirsky declined to comment beyond the company’s press release. Rexahn (NASDAQ: REXN) is also eliminating two positions and…
from https://www.bizjournals.com/baltimore/news/2019/09/25/maryland-biotech-looks-for-lifeline-following.html?ana=RSS&s=article_search
via https://baltimorecheckbook.tumblr.com/post/187941570897
No comments:
Post a Comment